Intraindividual tumoural heterogeneity (ITH) is a hallmark of solid tumours and impedes accurate genomic diagnosis and selection of proper therapy. The aim of this study was to identify ITH of ovarian high-grade serous carcinomas (OSCs) and to determine the utility of ascitic cancer cells as a resource for mutation profiling in spite of ITH. We performed whole-exome sequencing, copy number profiling and DNA methylation profiling of four OSC genomes by using multiregional biopsies from 13 intraovarian lesions, 12 extraovarian tumour lesions (omentum/peritoneum), and ascitic cells. We observed substantial levels of heterogeneity in mutations and copy number alterations (CNAs) of the OSCs. We categorized the mutations into 'common', 'shared' and 'private' according to the regional distribution. Six common, eight shared and 24 private mutations were observed in known cancer-related genes. Common mutations had a higher mutant allele frequency, and included TP53 mutations in all four OSCs. Region-specific chromosomal amplifications and deletions involving BRCA1, PIK3CA and RB1 were also identified. It is of note that the mutations detected in ascitic cancer cells represented 92.3-100% of overall somatic mutations in the given case. Phylogenetic analyses of ascitic genomes predicted a polyseeding origin of somatic mutations in ascitic cells. Our results demonstrate that, despite ITH, somatic mutations, CNAs and DNA methylations in both 'common' category and cancer-related genes were highly conserved in ascitic cells of OSCs, highlighting the clinical relevance of genome analysis of ascitic cells. Ascitic tumour cells may serve as a potential resource for discovering somatic mutations of primary OSC with diagnostic and therapeutic relevance.
Introduction
Ovarian cancer is the most lethal gynaecological malignancy. Ovarian high-grade serous carcinoma (OSC) is the most common type of ovarian cancer, and most OSCs develop from intraepithelial carcinomas in the fallopian tube [1] . OSC is frequently accompanied by seeding within pelvic/abdominal cavities of cancer cells that may form large masses and lead to rapid clinical deterioration of the patient [2] . Like that of other malignancies, the prognosis of patients with OSC is closely related to tumour burden and metastatic status, including pelvic/abdominal metastasis [3] . Therefore, a better understanding of the molecular and genetic mech58 YJ Choi et al characterized by its spread to the peritoneum and the development of malignant ascites [2, 3] . The malignant ascites is known to serve as a major cellular source for the development of pelvic/abdominal metastases and disease recurrence [3, 4] , but genetic and epigenetic profiling of ascites in OSC has not been thoroughly investigated.
It is widely believed that a cancer forms via clonal expansion of a single cell from which new subclones emerge in a stepwise manner [5] [6] [7] . Through clonal expansion during cancer progression, a cancer inevitably generates intraindividual tumoural heterogeneity (ITH) at both genetic and epigenetic levels [6, 7] . Recently, Hoogstraat et al analysed three ovarian cancers (two OSCs and one carcinosarcoma) by using multiregion biopsies of primary and omentum/peritoneum tumours, and found substantial levels of genetic ITH [8] . Additional reports have also demonstrated genetic ITH in ovarian cancers [4, [8] [9] [10] , suggesting that the mutational landscape of a given cancer genome cannot be completely determined without considering ITH. Recently, another study analysed whole-exome sequencing-based mutational profiling of ovarian cancer cells in ascites obtained from a cohort of patients with variable disease outcomes [11] . However, the potential of additional cellular resources such as malignant ascites to prioritize molecular targets in the presence of ITH has not been determined.
In this study, we performed multiregion biopsies from intraovarian (IO) and extraovarian (EO) (omentum and peritoneum) tumour lesions, and obtained cancer cells from the ascites for four cases of OSC. Integrated genomic analyses (whole-exome sequencing, copy number profiling, and DNA methylation profiling) identified a substantial level of genetic and epigenetic ITH among the tissues analysed. In addition, we found that mutation profiling of ascitic cells in the OSC patients recovered the majority of somatic mutations found across regional biopsies of the corresponding tumours.
Materials and methods

Primary and metastatic ovarian cancer tissues and ascites
All specimens from the patients in this study were obtained with appropriate consent and approval of the institutional review board of the Catholic University of Korea, College of Medicine and Korea Gynaecological Cancer Bank. Four to nine different ovarian cancer areas from IO and EO lesions that were at least 1 cm apart as well as 50 ml of ascites were collected from the four OSC patients (supplementary material, Table S1 ). To properly evaluate the evolutionary relationships of regional biopsies in the IO tumour masses, we took the biopsies in each IO mass according to the size of the IO tumour mass. The sizes of the IO and EO tumour masses for four OSC cases are shown in the Figure 1 . All picked tissues from tumour areas were frozen, sectioned, and stained with haematoxylin and eosin (H&E) (supplementary material, Figure S1 ). Two pathologists selected areas with rich tumour cell populations (at least 70%), which were subsequently used in the study. Ascitic cells were pelleted by centrifugation (28000 g for 1 min., 2 times), embedded in tissue-freezing compound, frozen, cut, and stained with H&E. The pathologists confirmed that there was at least 30% tumour content in the pellets. For genomic DNA extraction, we used the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany), according to the manufacturer's recommendations.
Multiregion mutation analyses by whole-exome sequencing
Whole-exome sequencing for the tumours from multiregion biopsies and for matched normal peripheral blood cells was carried out with the (Illumina, San Diego, CA, USA) HiSeq2500 platform, with the exome regions being captured with the Agilent SureSelect Human All Exon 50 Mb kit (Agilent Technologies, Santa Clara, CA, USA). The mean coverage depths of normal samples and IO, EO and ascitic tumours were × 92-144, ×70-145, ×112-143, and × 187-211, respectively (supplementary material, Tables S1 and S2). The paired-end sequencing reads were aligned onto the human reference genome (hg19) with Burrows-Wheeler aligner software [12] . The Genome Analysis ToolKit [13] Picard (http:// picard.sourceforge.net) and Samtools (http://samtools .sourceforge.net) were applied to the sequencing reads for basic processing and management, including local realignments and score recalibration of sequencing reads. The somatic variations were identified by comparing the tumour and matched normal sequencing datasets. The somatic point mutations and indels were called by the use of MuTect and Indelocator, respectively [13, 14] . The functional annotations of the somatic variants were performed with the ANNOVAR package [15] .
Mutation categories
The mutations were classified into four categories: three spatial events ('common', 'shared', and 'private') and 'ascites-specific' events. Common events were those observed in all of the regional biopsies of a given tumour (IO/EO lesions), shared events were those observed in two or more regional biopsies, but not in all, and private events were those that were observed in only one lesion, either IO or EO. The ascites-specific category included the mutations found only in ascitic cells, and not in solid lesions (IO/EO lesions). Feature Extraction software. The intensity for each probe was corrected for background information, and the aCGH data were produced by probe-level summarization. Segmentation was performed with a circular binary segmentation algorithm [16] . We also inferred the purity and ploidy by using the ABSOLUTE package for each regional biopsy [17] . The log 2 ratios were further adjusted by the estimated purity and ploidy levels, as described previously [18] . We considered adjusted log 2 ratios of ≤0.2 or < 0.2 as chromosomal gains and losses, respectively. The data have been uploaded to the NCBI SRA database (accession number: SRP080983). In addition, we called copy number alterations (CNAs) from exome sequencing data by using Excavator [19] (supplementary material, Table S3 ).
DNA methylation profiling
The DNA methylation profiles of ascitic cells and of a randomly selected IO biopsy and EO biopsy from each OSC case (supplementary material, Table S1 ) were obtained with the Infinium HumanMethylation450 BeadChip platform. The methylation levels at CpG sites 60 YJ Choi et al were quantified by β-values, after preprocessing and normalization steps according to the manufacturer's instructions. The differentially methylated CpG sites were identified by differences in the β-values. The hypermethylated and hypomethylated CpGs were defined as the sites whose β-values were higher and lower, respectively, than 0.2 as compared with the normal sample.
Phylogeny analysis
The phylogenetic relationship was inferred from the somatic mutations with mutant allele frequencies (MAFs) of >0.1 in the regional biopsies of the given samples. The phylogenetic trees were constructed with a maximum parsimony method implemented in the PHYLIP software package, as described previously [20, 21] . In order to identify the genomes of ascitic cells, the somatic mutations of simulated regional biopsies were constructed by mixing the sequencing datasets. After merging of the sequencing reads of original regional biopsies, the simulated datasets were generated with a prevalence of 20% by random down-sampling from the whole merged datasets. Then, the somatic variations were identified with an identical method. The phylogenetic trees for the simulated datasets were visualized with Dendroscope [22] .
Results
Samples and clinical data
We analysed tissues from four patients with OSC (International Federation of Gynecology and Obstetrics stage III-IV) without a family history of ovarian/breast cancers. Ovarian cancer tissues and ascites were collected during cytoreductive surgery. Three of the four were naive ovarian cancer patients who had not received neoadjuvant chemotherapy, whereas one patient was treated with neoadjuvant chemotherapy before tissue collection ( Table 1) . Two of the OSC patients carried BRCA2 germline mutations that have not been previously reported (Breast Cancer Information Core; https:// research.nhgri.nih.gov/projects/bic) -the frameshift deletion c.6723_6724del (p.T2241fs; OSC3) in one, and the missense mutation c.G7807C (p.A2603P; OSC4) in the second. Although patient OSC4 did not have a family history of either ovarian or breast cancer, a concurrent breast cancer was detected in this patient. According to the database for non-synonymous single-nucleotide polymorphism (SNP) functional predictions [23] , the missense mutation p.A2603P was predicted to be deleterious (SIFT score, D; PolyPhen2 score, D; and Mutation Taster, D).
Regional distribution of genomic alterations in ovarian cancer genomes
To investigate the mutational ITH and the evolutionary relationships of ovarian cancers, we performed multiregion whole-exome sequencing for samples of four OSCs that included one to six IO tumour biopsies, three EO tumour biopsies, and ascitic cells from each case (supplementary material, Table S1 ). Overall, whole-exome sequencing of 25 IO/EO tumour genomes revealed 88-166 somatic variants in coding regions per biopsy (median of 107 exonic mutations), corresponding to 168-257 somatic coding variants per patient ( Figure 1A ). Full lists of the exonic mutations identified are available in supplementary material, Tables S4-S8. The mutational abundance of IO tumour genomes and that of EO tumour genomes were not statistically different (p = 0.387; unpaired t-test).
We categorized the somatic mutations observed in the four patient cases according to their regional presentation (spatial mutation categories; Figure 1A ). In the OSCs, 19.5-36.9% of somatic mutations were common (i.e. observed across all regional biopsies) and 37.1-53.3% were private (i.e. specific to one regional biopsy). The remaining mutations (19.6-34.1%) were classified as shared mutations. A similar abundance of private and common mutations suggested a substantial level of ITH. In all OSC cases, the MAF of common mutations was significantly higher than that of the other two categories (shared and private) ( Figure 1B ), suggesting that common mutations were likely to be clonal and may have arisen earlier during tumour evolution. When we dissected the somatic mutations according to their potential functional consequences (i.e. silent and non-silent mutations) and their mutation spectra (i.e. sequence composition), we found no substantial differences in their relative abundance with respect to the spatial mutation categories (supplementary material, Tables  S4-S8) .
A total of 2607 CNAs were detected from the 25 regional biopsies (mean of 105 CNAs) (supplementary material, Tables S9-S12). Common, shared and private CNA events were observed in 30.5-72.0%, 18.0-51.7% and 3.1-17.8% of the OSCs, respectively. We detected 29 recurrent (i.e. observed in two or more of the four OSC cases) loci in the common category (supplementary material, Table S13), 20 of which harboured genes previously reported to be associated with OSC genomes [24] . Sanger sequencing (validation rate of 88.9%; supplementary material, Figure S2 ). TP53 mutations -two truncating mutations (one nonsense mutation and one frameshift indel) and two missense mutations -were detected as common categories in all four OSC cases ( Figure 1A ). NTRK3 mutation was observed in different spatial categories (shared in OSC2 and common in OSC4), suggesting that these mutations might have occurred at different evolutionary time points for the given cases.
To infer the pathway-level enrichment of singleton mutations, we performed gene set enrichment analyses with DAVID (http://david.abcc.ncifcrf.gov) (supplementary material, Table S14) [26] . Genes related to 'cell adhesion' were enriched in all of the categories except for private EO. Those related to 'Ras signalling' were enriched in the common and shared categories. The private IO mutations were related to 'DNA alkylation' and 'DNA methylation'. aCGH also revealed the heterogeneous nature of OSC genomes in terms of CNAs (supplementary material, Tables S9-S12), although the extent of CNA-based ITH was less than that of mutational ITH. Of the 29 recurrent common loci, 27 (93.3%) were also seen as shared or private events in at least one of the other cases (supplementary material, Table S13 ). For example, a focal gain of 3q harbouring PIK3CA was identified as common in two cases (OSC3 and OSC4), but as private in one case (OSC1). Chromosomal losses of 17q and 13q harbouring BRCA1 and RB1, respectively, were categorized as common in three cases (OSC1, OSC2, and OSC3) but as shared in the other case (OSC4) (Figure 2 ). We also called CNAs from our whole-exome sequencing data, and compared the results with those from array-based CGH. We observed that CNA calls made by sequencing and array-based CGH were largely concordant with each other (supplementary material, Table S3 ).
Ascitic cells integrate the ITH of OSC genomes
We performed whole-exome sequencing of ascitic cells, and compared their somatic mutations with those of regional biopsies in the given patients ( Figure 3A) . For the four OSC genomes, ascitic cells showed 76-141 exonic mutations per genome (supplementary material, Tables S4-S8 ). The ascitic cell genomes possessed nearly all of the common events (84.0-100%), including TP53, KMT2D, RB1, CRTC3, PRDM16 and IDH1 in the cancer Gene Census ( Figure 1A) . A considerable number of shared mutations (22.9-75.8%) were also discovered in the ascitic cells, but only a small fraction of private mutations (0.8-9.3%) were found in ascitic cells. It is of note that the relatively small fraction of ascites-specific exonic mutations (13.7-33.7% of ascites genome-derived mutations) suggests that the mutation set of ascitic cells represent a proxy that integrates the entire mutational landscape of a given tumour instead of an independent tumour biopsy ( Figure 3A) . Also, we observed that mutation features such as potential functional consequences and mutation spectra did not show any significant differences between ascitic cells and the solid regional biopsies (p > 0.05) ( Figure 3B, C) , further supporting the above hypothesis.
aCGH revealed that chromosomal alterations of ascitic cells might also integrate the ITH of OSC genomes. Among them, 92.2-99.0% of the CNAs in ascitic cells were found in the regional biopsies (supplementary material, Table S15), and 82.4-100% of common, 60.3-80.3% of shared and 25-61.9% of private CNAs in the regional biopsies were identified in the ascitic cell genomes (supplementary material, Tables S9-S12).
Microarray-based DNA methylation profiling was compared among ascitic cells, one IO biopsy and one EO biopsy from each case (supplementary material, Table S1 and Figure S3) . Most of the hypermethylated and hypomethylated CpGs in ascitic cells overlapped with those of IO and EO tissues. Among them, hypermethylated genes (AMT and HOXA9) [24, 27] and hypomethylated genes (CLND4 and MAL) are known cancer-related genes (supplementary material, Figure S3 ) [28, 29] . Only 0.0-11.2% and 0.0-2.9% of hypermethylated and hypomethylated CpGs, respectively, were ascites-specific (supplementary material, Figure S3 ), further suggesting that ascitic cells rarely acquire additional epigenetic aberrations. Figure 2 . CNA profiles. (A) OSC1, OSC2 and OSC4 harbour a 3q gain encompassing PIK3CA (3q) as a common event, whereas OSC3 harbours this as a shared event. The 3q gain is also present in ascitic cells. (B, C) OSC1, OSC2 and OSC3 harbour a 13q loss encompassing RB1 and a 17q loss encompassing BRCA1 as common events, whereas OSC4 harbours these as shared events. Asterisks denote the regional samples without any CNAs.
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In silico reconstruction of OSC genomes predicts the relationship between solid tumours and ascitic cells
Phylogenetic trees inferred from genomic data may represent the evolutionary life history of individual tumours, as discussed in previous literature [20, 21] . In the present study, the phylogenetic relationships among the multiregional biopsies (IO/EO lesions and ascitic cells) of a given sample were constructed from the mutation data by the use of maximum parsimony (Figure 4 ; supplementary material, Figure S4 ). The inferred evolutionary patterns appeared as branched evolution rather than constant or linear evolution. Noticeably, in all four cases, ascitic cells were segregated from the other solid tumour regions. Although the early divergence from the 'trunk' in the phylogenetic trees may represent the early occurrences of the corresponding clones or the mutations, this should be interpreted with care for ascitic cells. Therefore, we tested two hypotheses for the occurrence of ascitic cells as: (1) early seeding (i.e. early evolutionary divergence from the tumour origin); or (2) polyseeding (i.e. ascitic cells originating from the multiregions).
In silico analysis was performed to evaluate whether the genomes of ascitic cells truly diverged during an early evolutionary phase, or whether the seemingly early divergent pattern was a distinct pattern of mixed cells from multiple regions. We found that mixed sequencing datasets of multiregional biopsies showed a pattern of early divergence from the root, in accordance with the observed phylogenetic patterns (supplementary material, Figure S5 ). In addition, pairwise comparison of MAF of the somatic mutations between solid tumour legions and ascitic cells showed that the mutational abundances of solid tumours and ascitic cells were significantly correlated (p < 0.05 for all OSC cases) (supplementary material, Figure S6 ). Taken together, these data suggested that ascitic cells originated from the multiple solid tumour lesions rather than by early seeding, supporting the polyseeding origin of the ascitic tumour cells.
In addition, the phylogenetic tree showed that 'IO tissue to EO tissue' was not the sole spreading pattern of the OSC genomes, which leads to six different possible patterns of spread (supplementary material, Figure S7 ). As a previous study reported [4] , some of the EO tissues segregated from other EO tissues, and, intriguingly, our phylogenetic tree showed that some EO tissues even spread back to ovarian tissues (supplementary material, Figure S7 ). For example, the tree topology of case OSC3 showed five spreading patterns, as follows: (1) ipsilateral IO spread; (2) from an IO tissue to an EO tissue; (3) from an EO tissue to another EO tissue; (4) from an EO tissue to a contralateral IO tissue; and (5) from an IO tissue to a contralateral IO tissue. Another predicted pattern, which describes spread from an EO tissue to an ipsilateral IO tissue, was present in OSC4 (supplementary material,, Figure S7 ).
Discussion
In this study, we attempted to identify the genetic ITH and subclonal architectures of OSC genomes in association with ascitic cell genomes by performing whole-exome sequencing, copy number profiling, and DNA methylation profiling. First, we observed high levels of mutational and CNA ITH in four OSC genomes. We also observed that the somatic mutations in different spatial categories were enriched for distinct ontology terms, suggesting that functional constraints may be operative during OSC genome evolution. Second, in spite of the ITH, the somatic mutations, CNAs and DNA methylations in both the common category and cancer-related genes were highly conserved in ascitic cells, highlighting the clinical relevance of genome analysis of ascitic cells, e.g. as preoperative or postoperative cellular resources for mutational profiling of ovarian cancer genomes. Supporting this, the phylogenetic data and the mutational abundance of OSC suggested that the ascitic cells might have originated from multiple regions of solid OSC lesions.
Our data support previous studies demonstrating that OSC genomes show ITH [4, 11, 30] , and raise the question of whether there would be a way to overcome the ITH. We observed that the majority of somatic mutations and CNAs in multiregions (Figure 3 ; supplementary material, Table S15) were detected in ascitic cells, and that methylation patterns in the multiregions were also largely conserved in ascitic cells (supplementary material, Figure S3 ). The development of malignant ascites is a distinct feature of both primary and recurrent OSC patients [3, 31] . Thus, the genomes of ascitic OSC cells may be widely used as a valuable tool to diagnose overall heterogeneous genomes in OSC patients.
OSC genomes are known to harbour ubiquitous TP53 somatic mutations [4, 32] , and our data showed that TP53 somatic mutations (common events in all of the four OSC patients) were co-detected in ascitic cells. Currently, therapy and vaccine trials targeting the TP53 gene are under investigation for both primary and recurrent OSCs [33] [34] [35] . TP53 mutations, and other mutations with potential therapeutic relevance, can be preoperatively and postoperatively identified in ascitic cells to facilitate such approaches. In addition, ascitic cells can serve as cellular resources to monitor the treatment response and emergence of resistant clones in OSCs, and possibly any other ascites-producing cancers.
Together with lines of evidence suggesting that the mutation set of ascitic cells represent a proxy that integrates the entire mutational landscape of a given OSC, our in silico analysis further revealed clues for identifying the origins of ascitic cells. Ascites is known to be an independent prognostic factor for promotion of tumorigenesis [3, 32, 36] ; however, the spatiotemporal patterns of ascitic cell formation have not been completely clarified [37] . Schwarz et al showed that phylogenetic reconstruction of OSC revealed early divergence of the ascites sample from the root [4] , which was also true in our data. In the present study, simulated sequencingcorrelations (supplementary material, Figure S6 ). Thus, our results confirmed, at the genome level, the long-held theory that ascitic cells are shed from solid tumour lesions and that physical recirculation of ascites fluid facilitates dissemination [4] .
Phylogenetic analysis predicted the cancer cell spreading patterns of OSCs (supplementary material, Figure S7 ). Such unfixed spreading patterns, which are unlike what is seen in other types of cancer [19, 20] , might result from the peritoneal dissemination caused by recirculation of ascitic fluid. The interpretation of phylogeny requires caution, especially when a limited number of regional biopsies are used, owing to potential regional biases. However, a recent report suggests that the metastasized cells may re-infiltrate the primary tumour sites [38] , and this hypothesis is in agreement with our observation made in OSC4, whereby the biopsy of IO tumour segregated from the phylogenic branches of EO tumours. In addition, further investigation is required regarding technical issues (e.g. the sensitivity and precision of mutation calling [39] ) and known biological issues (e.g. the presence of variegated mutations [40] ) that may interfere with accurate inference of the evolutionary relationships between the regional biopsies.
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